September 30, 2019
NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark  this link  for your convenience.

NRG Oncology is seeking an experienced Patient Advocate to serve as Chair for its Patient Advocate Committee 
Application Deadline: 10/15/19

  Read more



GOG-0241: Terminated effective April 15, 2019; version date: June 10, 2014 (posted on  CTSU)

NRG-CC002: Terminated effective February 9, 2019; version date: September 22, 2015  (posted on  CTSU)



NRG-GY005: Amendment 11; version date: September 6, 2019 (posted on  CTSU)


RTOG 1308:  Amendment 5; version date: August 20, 2019 (posted on  CTSU)




NRG-GI004: Bioclinica Reminders Memo (posted on CTSU)


NRG-GU007: Reminder that the study was reopened to accrual with protocol amendment 1 on July 17, 2019. The protocol is currently accruing to the phase I portion at dose level 1 of the study (posted on CTSU)


NRG-GY005: CEC Whole Blood Shipping Address memo (posted on CTSU)

NRG-GY009: Block Submission Reminder memo (posted on CTSU)


NRG-GY018: MMR and PD-L1 Kit Ordering (memo posted on CTSU)

Form TR for Biospecimens Shipped to NRG Biospecimen Bank-Columbus Read more


Biospecimen Bank-Columbus & SDMC Undergoing Refurbishment Read more



The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, and NRG-CC004. Space is limited so register now and reserve your seat.  The next webinar training is scheduled for Wednesday, October 9.




Safety updates have been issued for the following studies:
















NRG Oncology is seeking an experienced Patient Advocate to serve as Chair for its Patient Advocate Committee 

This volunteer position provides the selected individual the responsibility of facilitating and guiding the NRG Oncology Patient Advocate Committee (PAC) and program through a process to update its vision and create an action plan to build on its success. Read more

Call for Research Proposals

The NRG Oncology Colorectal Cancer subcommittee is seeking vendors and researchers with ctDNA expertise in the field.  An RFA for the randomized phase II/III colorectal prospective clinical trial, NRG-CR1902 is posted here. We are seeking a biomarker assay partner to perform CLIA-certified assay testing of patients to detect ctDNA from plasma samples at the time of enrollment and at end of completion of planned adjuvant therapy.  Responses to the RFA no later than Friday, November 1, 2019. Please direct responses and any questions to Chet Cornman at

ESMO 2019: Trametinib Improves Outcomes for Women with Low-Grade Serous Carcinoma of the Ovary/Peritoneum on NRG-GOG 0281

NRG Oncology and the National Cancer Research Network (NCRN) collaborated on a phase II/III clinical trial NRG-GOG 0281 which compared treatment using the MEK inhibitor trametinib to the physician’s choice of standard of care treatment for women with low-grade serous ovary or peritoneal cancer (LGSOC). Results of this trial indicate that trametinib was able to improve progression-free survival (PFS) and objective response rate (ORR). Improvements in response duration and overall survival (OS) were also observed.   Read more


Dr. Abraham Appointed Cleveland Clinic Department Chair of Hematology/Medical Oncology

Congratulations to Jame Abraham, MD, FACP, vice chair of the NRG Oncology Research Review Committee, on his appointment as chair of the Department of Hematology/Medical Oncology at Cleveland Clinic. Read more.


New recommended HDC resources

New resources have been added to the NRG Oncology Health Disparities Committee Recommended Resources page on the NRG Oncology website (login required).

PSC Accepting Applications for CTN and CRA Committees and Working Groups
The NRG Oncology Protocol Support Committee (PSC) is accepting applications for membership on the Clinical Trial Nurse (CTN) Committee, Clinical Research Associate (CRA) Committee, and PSC Working Groups (Education and Training, Mentorship, Protocol Review, and Quality Control). CTN and CRA members must also be a member of a Working Group. If you are not currently a member of a working group, you may apply at the same time.


If you are interested in becoming a member of any of the committees or groups mentioned above, the Application Request forms, including instructions and descriptions, are posted here.


Click the link(s) below to download the specific application form and instructions (login required).

CTN Application

CRA Application

PSC Working Group Application


Applications are to be submitted by Monday October 21, 2019.  Please forward questions to:


Please note the following upcoming meeting and abstract submission deadline dates

Upcoming Meetings

European Society of Gynaecolocial Oncology (ESGO)  Biennial Nov 2-5, 2019; Athens, Greece

International Society for Quality of Life Research (ISOQOL)
; Oct 20-23, 2019; San Diego, CA

Society for Neuro-Oncology (SNO); Nov 20-24, 2019; Phoenix, AZ

Upcoming Abstract Submission Deadlines

American Association for Thoracic Surgery (AATS); Apr 25-28, 2020; New York, NY; due to publications committee Oct 1, 2019; meeting submission deadline Oct 15, 2019

American Society of Clinical Oncology (ASCO) GI
; Jan 23-25, 2020; San Francisco, CA; due to publications committee Sep 17, 2019; meeting submission deadline Oct 1, 2019

American Society of Clinical Oncology (ASCO) GU
; Feb 13-15, 2020; San Francisco, CA; due to publications committee Oct 8, 2019; meeting submission deadline Oct 22, 2019

European Society for Radiotherapy and Oncology (ESTRO); Apr 3-7, 2020; Vienna, Austria; due to publications committee Oct 9, 2019; meeting submission deadline Oct 23, 2019; Late submission Jan 15, 2020

Society of Gynecologic Oncology (SGO)
; Mar 28-31, 2020; Toronto, ON, Canada; meeting submission deadline Sep 17, 2019; Intl abstr  11-5-19; LBA 1-7-20

Society of Surgical Oncology (SSO)
; Mar 25-28, 2020; Boston, MA; due to publications committee Sep 16, 2019; meeting submission deadline Oct 7, 2019

NRG Oncology is proud to be an active participant of #CancerMoonShot.
This message was sent from to
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103

Update Profile/Email Address | Forward Email | Report Abuse